Hyperhemolysis in the Setting of Mixed-Autoimmune Hemolytic Anemia: A Rare Complication of COVID-19.

Division

Capital

Hospital

LewisGale Medical Center

Document Type

Case Report

Publication Date

12-12-2021

Keywords

SARS-CoV-2, autoimmune hemolytic anemia, covid 19, hyperhemolysis syndrome; immune thrombocytopenia purpura, mixed autoimmune hemolytic anemia

Disciplines

Hemic and Lymphatic Diseases | Immune System Diseases | Internal Medicine | Virus Diseases

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human pathogen known for its predilection on the respiratory system. Herein, we present a unique case in which a patient developed hyperhemolysis in the setting of mixed autoimmune hemolytic anemia (AIHA) secondary to SARS-CoV-2. A 33-years-old male with a past medical history of resolved immune thrombocytopenic purpura (ITP) presented to the hospital with symptoms of jaundice after being infected with SARS-CoV-2. On admission, his Hgb was 12.5 g/dL. Lab results showed indirect bilirubin of 13 mg/dL, LDH at 759 U/L, haptoglobin

Publisher or Conference

Cureus

Link to Full Text

Share

COinS